目的 探討鼻淵舒口服液聯(lián)合西替利嗪滴劑治療小兒過敏性鼻炎的療效。方法 選取2018年1月-2020年1月在南陽市第二人民醫(yī)院耳鼻咽喉科門診治療的過敏性鼻炎患兒108例為研究對象，隨機(jī)分為對照組和治療組，每組各54例。對照組患者口服西替利嗪滴劑，<6歲，0.5 mL/次，1次/d；≥ 6歲，1 mL/次，1次/d。治療組在對照組基礎(chǔ)上口服鼻淵舒口服液，<6歲，5 mL/次，3次/d，≥ 6歲，10 mL/次，3次/d。兩組患兒均連續(xù)治療10 d。觀察兩組的臨床療效和臨床癥狀緩解時間。比較兩組治療前后血清學(xué)指標(biāo)、免疫功能指標(biāo)和血清炎性因子水平的變化情況。結(jié)果 治療后，治療組總有效率是94.44%，顯著高于對照組81.48%（P<0.05）。治療后，治療組患兒的鼻塞、鼻癢、打噴嚏、流涕等臨床癥狀緩解時間明顯短于對照組（P<0.05）。治療后，兩組患兒免疫球蛋白（IgE）、腫瘤壞死因子α（TNF-α）、C反應(yīng)蛋白（CRP）水平均顯著降低（P<0.05）；治療后，治療組IgE、TNF-α、CRP水平顯著低于對照組（P<0.05）。治療后，兩組患兒CD3⁺、CD4⁺、CD4⁺/CD8⁺指標(biāo)均顯著增加（P<0.05）；治療后，治療組這些免疫功能指標(biāo)顯著高于對照組（P<0.05）。治療后，兩組患兒血清白細(xì)胞介素4（IL-4）、白細(xì)胞介素17（IL-17）、γ干擾素（IFN-γ）、Th1/Th2水平均顯著降低（P<0.05）；治療后，治療組血清炎性因子水平顯著低于對照組（P<0.05）。結(jié)論 鼻淵舒口服液聯(lián)合西替利嗪滴劑治療小兒過敏性鼻炎臨床效果顯著，能有效緩解患兒的臨床癥狀，可明顯改善機(jī)體的免疫系統(tǒng)及炎性反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the curative effect of Biyuanshu Oral Liquid combined with cetirizine in treatment of allergic rhinitis in children. Methods A total of 108 children with allergic rhinitis treated in the outpatient department of otorhinolaryngology of Nanyang Second General Hospital from January 2018 to January 2020 were selected as the research objects, and randomly divided into the control and the treatment group, with 54 children in each group. Children in the control group were po administered with Cetirizine Hydrochloride Drops, <6 years old, 0.5 mL/time, once daily; ≥ 6 years old, 1 mL/time, once daily. Children in the treatment group were po administered with Biyuanshu Oral Liquid on the basis of the control group, <6 years old, 5 mL/time, 3 times daily, ≥ 6 years old, 10 mL/time, 3 times daily. Both groups received continuous treatment for 10 d. The clinical efficacy and remission time of clinical symptoms in the two groups were observed. The changes of serological indexes, immune function indexes, and serum inflammatory factors before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 94.44%, significantly higher than that of the control group (81.48%, P<0.05). After treatment, the remission time of nasal congestion, nasal itching, sneezing, runny nose, and other clinical symptoms in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the levels of immunoglobulin (IgE), tumor necrosis factor (TNF-α), and C-reactive protein (CRP) were significantly decreased in both groups (P<0.05). After treatment, the levels of IgE, TNF-α, and CRP in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ were significantly increased in both groups (P<0.05). After treatment, these immune function indexes in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the levels of interleukin 4 (IL-4), interleukin 17 (IL-17), interferon (IFN-γ) and Th1/Th2 in the two groups were significantly decreased (P<0.05). After treatment, the level of these serum inflammatory factors in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Biyuanshu Oral Liquid combined with cetirizine has significant clinical effect in treatment of allergic rhinitis in children, and can effectively alleviate the clinical symptoms of children, and also can significantly improve the body's immune system and inflammatory response, which has certain clinical application value.

R987